SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress.
Conference Call & Webcast Details
| Date: | Wednesday, May 8th, 2024 |
| Time: | 4:30 p.m. ET |
| Participant Dial-In: | Toll Free: 1-833-630-1956 International: 1-412-317-1837 |
| Webcast Link: | https://edge.media-server.com/mmc/p/5z343pph/ |
Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.64 |
| Daily Change: | 0.02 1.23 |
| Daily Volume: | 327,795 |
| Market Cap: | US$15.880M |
November 13, 2025 November 06, 2025 September 17, 2025 September 16, 2025 September 15, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
